Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation

Technology appraisal guidance
Reference number: TA256
Published: 23 May 2012
Last updated: 02 July 2021

Atrial fibrillation (stroke prevention) - rivaroxaban: consultee and commentator comments on the ACD

Atrial fibrillation (stroke prevention) - rivaroxaban: AntiCoagulation Europe
Atrial fibrillation (stroke prevention) - rivaroxaban: Arrhythmia Alliance
Atrial fibrillation (stroke prevention) - rivaroxaban: Atrial Fibrillation Association
Atrial fibrillation (stroke prevention) - rivaroxaban: Bayer
Atrial fibrillation (stroke prevention) - rivaroxaban: Boehringer Ingelheim
Atrial fibrillation (stroke prevention) - rivaroxaban: Bristol Myers-Squibb and Pfizer
Atrial fibrillation (stroke prevention) - rivaroxaban: British Association of Stroke Physicians
Atrial fibrillation (stroke prevention) - rivaroxaban: Commissioning Support Appraisal Service
Atrial fibrillation (stroke prevention) - rivaroxaban: Department of Health
Atrial fibrillation (stroke prevention) - rivaroxaban: Medicines and Healthcare Products Regulatory Agency
Atrial fibrillation (stroke prevention) - rivaroxaban: National Clinical Guidelines Centre
Atrial fibrillation (stroke prevention) - rivaroxaban: NHS Berkshire cluster
Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Nursing
Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Pathologists and BSH
Atrial fibrillation (stroke prevention) - rivaroxaban: The British Cardiovascular Intervention Society
Atrial fibrillation (stroke prevention) - rivaroxaban: The Stroke Association

This page was last updated: 29 March 2012